Enlivex Ltd.
ENLV evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ENLV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ENLV
Enlivex Ltd. is a clinical-stage biopharmaceutical company developing Allocetra™, a macrophage reprogramming therapy for osteoarthritis and other inflammatory indications, with a dual strategy that also includes a treasury model anchored in decentralized prediction markets infrastructure.
Key risk: Going concern risk
Market Cap
$23.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 5 clinical trials for Enlivex Ltd..
Enlivex Ltd. is a clinical-stage biopharmaceutical company developing Allocetra™, a macrophage reprogramming therapy for osteoarthritis and other inflammatory indications, with a dual strategy that also includes a treasury model anchored in decentralized prediction markets infrastructure.
- Lead product candidate Allocetra™ is being developed for osteoarthritis, a degenerative joint disease affecting over 32.5 million adults in the U.S. [sec · filed 2025-04-30]
- Cash and equivalents were $2.4M as of 2025-12-31, with shareholders' equity of $23.6M [sec].
- The company expects existing resources to fund currently planned operations through the end of 2027 [sec · filed 2026-03-25].
- Enlivex has not generated any revenue from Allocetra™ or any other product candidate and may never be profitable [sec · filed 2026-03-25].
What works
- Allocetra™ targets a large unmet medical need in osteoarthritis, where current treatments are limited to pain management and joint replacement [sec · filed 2025-04-30].
- The company has a dual strategy combining clinical development with a treasury model anchored in decentralized prediction markets, which generated a non-cash gain of $1.631 billion in fair value of digital assets as of 2025-12-31 [sec · filed 2026-03-25].
- Enlivex believes its existing cash resources will be sufficient to fund operations through the end of 2027, providing a runway for ongoing development [sec · filed 2026-03-25].
What to weigh
- The company has a history of recurring operating losses and its ability to continue as a going concern depends on additional financial support [sec · filed 2026-03-25].
- Enlivex has not generated any revenue from its product candidates and may never achieve profitability [sec · filed 2026-03-25].
- Significant additional capital will be required to complete FDA and EMA approval processes, and the company may need to delay or reduce operations if funds are not obtained [sec · filed 2026-03-25].
- The company's long-term capital requirements are uncertain and depend on many factors, including clinical trial results and regulatory outcomes [sec · filed 2026-03-25].
From the filings
Quoted directly from source documents.
Allocetra™ is being developed for osteoarthritis, a large U.S. market.
“The Company is focused on osteoarthritis as its main chronic inflammatory indication. Osteoarthritis is a degenerative joint disease, characterized by low-grade inflammation, that affects more than 32.5 million adults in the United States.”
SEC filings · April 30, 2025
The company has not generated revenue and may never be profitable.
“We have not generated any revenue from Allocetra™ or any other product candidate, and we may never be profitable;”
SEC filings · March 25, 2026
Existing cash resources are expected to fund operations through end of 2027.
“we anticipate that our existing resources will be sufficient to maintain our currently planned operations, including our continued product development, through the end of 2027.”
SEC filings · March 25, 2026
The company operates a dual strategy including a treasury model in decentralized prediction markets.
“We operate a dual strategy that combines clinical development in quality longevity therapeutics with a treasury model anchored in decentralized prediction markets infrastructure through the RAIN protocol.”
SEC filings · March 25, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Recurring operating losses and dependence on additional financing for continued operations [sec · filed 2026-03-25]
- No revenue from products — No revenue generated from Allocetra™ or any other product candidate; may never be profitable [sec · filed 2026-03-25]
- Need for substantial capital — Significant additional funds required for FDA/EMA approval; may delay or reduce operations if not obtained [sec · filed 2026-03-25]
- Clinical and regulatory uncertainty — Outcomes of clinical trials and regulatory approvals are uncertain and could affect capital needs [sec · filed 2026-03-25]
What to watch
- Progress of Allocetra™ clinical trials in osteoarthritis and any updates on regulatory interactions [sec · filed 2026-03-25]
- Changes in cash position and any new financing or partnership agreements to extend runway beyond 2027 [sec · filed 2026-03-25]
- Developments in the digital asset treasury strategy and its impact on financial results [sec · filed 2026-03-25]
- Any announcements regarding additional indications or strategic shifts in the pipeline [sec · filed 2026-03-25]
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Enlivex Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Enlivex Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$3.1M
| Holder | Shares | Value |
|---|---|---|
| diametric capital, lp | 1,483,178 | $1.4M |
| ark investment management llc | 628,310 | $584K |
| prelude capital management, llc | 225,738 | $210K |
| two sigma investments, lp | 146,412 | $136K |
| bank of america corp /de/ | 130,401 | $121K |
| renaissance technologies llc | 128,192 | $119K |
| goldman sachs group inc | 102,093 | $95K |
| xtx topco ltd | 100,362 | $93K |
| morgan stanley | 98,333 | $91K |
| geode capital management, llc | 80,560 | $75K |
Showing top 10 of 33 institutional holders of Enlivex Ltd.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 0.2%
- Days to cover
- 0.7
- Shares short
- 535,106
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ENLV short interestFrequently asked questions
What is the AI investment thesis for Enlivex Ltd.?
Enlivex Ltd. is a clinical-stage biopharmaceutical company developing Allocetra™, a macrophage reprogramming therapy for osteoarthritis and other inflammatory indications, with a dual strategy that also includes a treasury model anchored in decentralized prediction markets infrastructure.
Who is the CEO of Enlivex Ltd.?
Dr. Oren Hershkovitz Ph.D. is the chief executive officer of Enlivex Ltd. (ENLV).
Where is Enlivex Ltd. headquartered?
Enlivex Ltd. (ENLV) is headquartered in Ness Ziona, Israel.
What therapeutic areas does Enlivex Ltd. focus on?
Enlivex Ltd. develops therapies across Oncology, Infectious Disease, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.